reference/33563867

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33563867

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Research Support, N.I.H., Extramural
endingPage	437
issn	1558-7673
issueIdentifier	7
pageRange	433-437
publicationName	Clinical Genitourinary Cancer
startingPage	433
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_5c57081d51dc8f551c1f9a0540206216
bibliographicCitation	Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec;5(7):433–7. doi: 10.3816/cgc.2007.n.031. PMID: 18272025.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ccd7944889f31b9214cae04ce71d7e43 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3900a5abe65bb8644127b10201619dc2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bedcef0a1d9044049056ecb22a5d2df1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0869-7928 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f26f989da82c47301810cdf12670cdf6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c720a6679184d5fb98dbf9a8e196e32f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_be7c0cbf54df46e812e4e18a3709b1df http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fdd848bb8e602828a43280b142b51ec4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3258e6867578ccd358b7eb39cb202d04 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5944a9062b1258c1e5a11a7f8fdb80f4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5044aaa96c18139649a3c8697c06c0aa http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_83ac44e65c6d54d1b898b225009cd063
date	200712
identifier	https://pubmed.ncbi.nlm.nih.gov/18272025 https://doi.org/10.3816/cgc.2007.n.031
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32764 https://portal.issn.org/resource/ISSN/1558-7673
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial
discusses	http://id.nlm.nih.gov/mesh/M0457532 http://id.nlm.nih.gov/mesh/M0150739 http://id.nlm.nih.gov/mesh/M0016734 http://id.nlm.nih.gov/mesh/M0001103 http://id.nlm.nih.gov/mesh/M0276105
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D010767Q000031 http://id.nlm.nih.gov/mesh/D051057Q000037 http://id.nlm.nih.gov/mesh/D047428Q000627 http://id.nlm.nih.gov/mesh/D009364Q000188 http://id.nlm.nih.gov/mesh/D011471Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D010767Q000009 http://id.nlm.nih.gov/mesh/D010767Q000627 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000726Q000627 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6965 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fe0d872c4ea3e7d9f07488fc82841cc8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_472b28cee6c37ce9d58de4aa1dc6d7ef http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.77 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8126 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148177 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10634 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10751 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135990222

Showing number of triples: 1 to 63 of 63.